Cancer is the leading cause of death in dogs over the age of two years. Drug therapies are constantly evolving to target various aspects of cancer cell proliferation. Bouvardin, a protein synthesis inhibitor, has recently been identified as an agent that when combined with radiation therapy or chemotherapy, can decrease the survival of cancer cells. With the support of American Humane, this project studied inhibited canine tumor cells (in-vitro study) in a dose-dependent manner. There was a varying response to the drug depending on the type of cancer cells. Notably, Bouvardin had the greatest effect on melanoma and hematopoietic-line cancer cells. These results highlight the future potential for Bouvardin to be used as a single chemotherapeutic drug or in combination with other known therapies. This study’s findings offer hope for many dogs suffering with certain types of cancer.